|1.||Mousa, Shaker A: 10 articles (03/2015 - 01/2002)|
|2.||Leys, Didier: 9 articles (10/2012 - 09/2005)|
|3.||Bath, Philip M W: 9 articles (10/2012 - 09/2005)|
|4.||TAIST Investigators: 8 articles (10/2012 - 03/2006)|
|5.||O'Neill, Desmond: 8 articles (10/2012 - 07/2006)|
|6.||Gray, Laura J: 7 articles (10/2012 - 09/2005)|
|7.||De Deyn, Peter Paul: 7 articles (10/2012 - 07/2006)|
|8.||Hull, Russell D: 6 articles (09/2013 - 12/2003)|
|9.||Sprigg, Nikola: 6 articles (10/2012 - 09/2005)|
|10.||Ringelstein, E Bernd: 5 articles (10/2012 - 11/2007)|
|1.||Venous Thrombosis (Deep-Vein Thrombosis)
03/01/2003 - "Low molecular weight heparins, specially tinzaparin, are a safe and effective treatment for deep vein thrombosis in our unit."
10/01/2007 - "Phase 1 of the study identified criteria for the safe discharge of selected patients; phase 2 treated a cohort of low-risk patients with PE as outpatients with tinzaparin using existing deep venous thrombosis services. "
10/01/2009 - "One patient developed a deep venous thrombosis while taking tinzaparin, and three patients developed thromboembolic complications while off tinzaparin. "
01/01/2008 - "Twenty-two pregnant patients with a confirmed deep venous thrombosis were treated with tinzaparin either in a once- or twice-daily regimen. "
09/01/2007 - "Tinzaparin in long-term treatment of deep venous thrombosis."
10/01/2012 - "Quality of life after ischemic stroke varies in western countries: data from the tinzaparin in Acute Ischaemic Stroke Trial (TAIST)."
02/01/2011 - "Relationship between baseline blood pressure parameters (including mean pressure, pulse pressure, and variability) and early outcome after stroke: data from the Tinzaparin in Acute Ischaemic Stroke Trial (TAIST)."
01/01/2009 - "The relationship between baseline blood pressure and computed tomography findings in acute stroke: data from the tinzaparin in acute ischaemic stroke trial (TAIST)."
11/01/2007 - "We used data from the Tinzaparin in Acute Ischaemic Stroke Trial (TAIST) to assess the relationship between sex and QoL after ischemic stroke. "
11/01/2007 - "Sex differences in quality of life in stroke survivors: data from the Tinzaparin in Acute Ischaemic Stroke Trial (TAIST)."
12/01/2012 - "Tinzaparin may have a more favorable benefit-risk ratio than VKA in patients with cancer and VTE."
12/01/2012 - "In cancer patients, a non-significant 38% VTE risk reduction in favor of tinzaparin was observed on treatment (RR=0.62 [0.30; 1.31]). "
03/01/2009 - "Long-term tinzaparin was at least as efficacious and safe as AVK for preventing recurrent VTE, especially in patients with cancer."
07/01/2005 - "Neither Tinzaparin nor NAC8000 inhibited primary subcutaneous tumor growth. "
09/01/2003 - "Administration of tumor cells (2 x 106) caused a rapid and significant fall in platelet count 15 min after injection (a sensitive marker of intravascular coagulation) in controls (939 +/- 37 vs. 498 +/- 94 x 106 mL-1, P < 0.01), but this was prevented by tinzaparin treatment (921 +/- 104 x 106 mL-1). "
08/01/2002 - "Tinzaparin may also be effective for unlabeled uses, such as prophylaxis of venous thromboembolism (VTE) after orthopedic, general, and abdominal surgery, although more data are needed to define the optimal dose for this indication. "
12/01/2011 - "Endpoints were presented using descriptive statistics for all pregnancies, and by reason for tinzaparin use (treatment of venous thromboembolism [VTE] and prophylaxis). "
07/01/2011 - "Rates of clinically relevant bleedings by day 90 were similar in the tinzaparin (11.9%) and UFH (11.9%) groups, as were rates of confirmed recurrent venous thromboembolism (VTE) (2.6 vs. 1.1%; p=0.34). "
08/01/2009 - "The rate of recurrent venous thromboembolism at 12 weeks was 3.3% in both groups (absolute difference 0%; 95% confidence interval -3.2-3.2), and at 1 year was 10.4%/8.3% in the tinzaparin/usual-care groups, respectively (difference 2.1%; 95% confidence interval -3.1-7.3). "
01/01/2007 - "Of 737 patients, 18 of 369 receiving tinzaparin (4.9%) had recurrent venous thromboembolism at 3 months compared with 21 of 368 (5.7%) receiving usual care (absolute difference, -0.8%, 95% confidence interval -4.1-2.4). "
12/01/2010 - "The objective of the present study was to evaluate the efficacy, safety and healthcare resource utilization of long-term treatment with tinzaparin in symptomatic patients with acute pulmonary embolism as compared to standard therapy. "
02/01/2006 - "Outpatient tinzaparin therapy in pulmonary embolism quantified with ventilation/perfusion scintigraphy."
01/01/2004 - "In the initial treatment of acute proximal DVT and pulmonary embolism, SC tinzaparin 175 anti-Xa IU/kg/day was at least as effective as adjusted-dosage intravenous (IV) UFH. "
10/27/2001 - "Tinzaparin reduced health care costs for pulmonary embolism due to easier administration, less complex laboratory tests, and personnel time savings. "
10/27/2001 - "[Economic assessment of the use of tinzaparin in the treatment of acute pulmonary embolism in France]."
|1.||Low-Molecular-Weight Heparin (Heparin, Low Molecular Weight)
|3.||Aspirin (Acetylsalicylic Acid)
|7.||Dalteparin (Dalteparin Sodium)
|8.||Nadroparin (Nadroparin Calcium)
|10.||certoparin (certoparin sodium)
|1.||Renal Dialysis (Hemodialysis)
|4.||Hip Replacement Arthroplasty (Total Hip Replacement)
|5.||Blood Transfusion (Blood Transfusions)